The Motley Fool

All I Want For Christmas Is… GlaxoSmithKline plc

FTSE 100 pharmaceuticals company GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been a favourite of mine for a while. The sector has been a reliable source of income for investors because it tends to perform well regardless of the economic cycle. Unfortunately, there are always going to be sick people in need of treatment, creating a reliable revenue stream for the big pharma companies. 

However, I wouldn’t buy a share just because it happens to operate in a desirable sector. GSK has excelled on many counts. Since 2009, it has achieved more Food and Drug Administration approvals of new molecular entities, or new drugs to me or you, than any other company, a fairly impressive achievement.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

It only has one “blockbuster” drug, Advair, that accounts for over £1bn of sales. Unfortunately its patent has already expired, and its £5bn sales are being put under pressure from generics. Management are confident, however, that the seven respiratory treatments in late-stage development should maintain the company’s leading position in respiratory treatment over the long term.

With 40 NMEs in late-stage development and a great R&D record, Glaxo has a pipeline that should carry it comfortably into the future. While we wait for some of these to develop, the company pays a 5.4% dividend well covered by cash flow, even if earnings cover is a bit low at 0.9x.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Zach Coffell has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.